GWM
CODX

Geneos Wealth Management’s Co-Diagnostics CODX Stock Holding History

Geneos Wealth Management’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-13
Closed -$3K – 2845
2021
Q2 		$3K Hold
13
– – ﹤0.01% 2562
2021
Q1 		$3K Hold
13
– – ﹤0.01% 2783
2020
Q4 		$3K Hold
13
– – ﹤0.01% 2606
2020
Q3 		$5K Hold
13
– – ﹤0.01% 2160
2020
Q2 		$7K Buy
+13
New +$5.93K ﹤0.01% 2031

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
ARC
Advisor Resource Council Dallas, Texas $355M AUM 30.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geneos Wealth Management's CODX Position: Q3 2021 in Review

Geneos Wealth Management sold out of Co-Diagnostics (CODX) in Q3 2021, closing a stake of 13 shares — an estimated $3K sold.

Geneos Wealth Management first reported a position in CODX in Q2 2020 and held it in 5 quarters. The position peaked at $7K in Q2 2020. 78 funds tracked by Wall St. Rank hold CODX as of Q3 2021.

  • Geneos Wealth Management reported no remaining Co-Diagnostics position as of Q3 2021 after selling out during the quarter.
  • Geneos Wealth Management sold 13 Co-Diagnostics shares in Q3 2021, an estimated $3K.
  • Geneos Wealth Management first reported a position in Co-Diagnostics in Q2 2020 and held it in 5 quarters.
  • Geneos Wealth Management's Co-Diagnostics position peaked at $7K in Q2 2020.
  • 78 funds tracked by Wall St. Rank held Co-Diagnostics as of Q3 2021.

Based on Geneos Wealth Management's 13F filing for Q3 2021, filed 9 Nov 2021.